Company intelligence / Profile preview

Norgine

Ownership: Private
Employees: ~1400
Development stage: Commercial

Overview

Norgine has multiple approved products across various therapeutic areas including gastroenterology, oncology, and hematology. Recent developments include approval of IFINWIL for high-risk neuroblastoma in Australia and acquisition of Theravia to strengthen their rare disease portfolio.

Therapeutic areas: OtherGastroenterologyOncologyHematology
Modalities: Small moleculesChemical drugsPolymersRecombinant proteins
Industry: Biotech

Drug pipeline

20 assets

MOVIPREP

Approved

19 more assets in the full pipeline.

Request access →

Partnerships

Fennec PharmaceuticalsUS WorldMedsFaes Farma

Beyond the preview

Go deeper on Norgine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norgine.

Explore the full profile